When Luke checked in at Trius Therapeutics almost six months ago, he reported that the San Diego life sciences startup was on a roll, but not quite ready to talk about results of its early stage clinical trials. These days, CEO Jeff Stein says Trius is assessing how best to move ahead in its development of a new anti-bacterial drug, based on results that he characterized as very encouraging.
In developing the drug known generically as torezolid, Stein told me Trius hopes to crack a market for treating MRSA and other drug-resistant infections that is now dominated by Pfizer’s linezolid (Zyvox). He described linezolid, which was approved by the FDA in 2000, as a “blockbuster drug” that generates over $1 billion a year. Linezolid is the only approved compound in the oxazolidinone class of drugs, Stein says, “so for years, just about every anti-infective company has been interested in getting a follow-up drug to Zyvox.”
Trius quickly completed its early stage trials last year, and in January enrolled 180 patients with nasty skin infections in a mid-stage clinical trial. It’s intended to examine the safety and efficacy of torezolid administered orally at three dosage strengths once daily over a five-to-seven day course of treatment.
Trius says more than 90 percent of the germs infecting patients in the trial were Staph infections, and 70 percent of the Staph infections were the “superbugs” known as MRSA, for Methicillin-Resistant Staphylococcus aureus. Trius intends to provide more detailed results of its trial in two or three months, but Stein told me, “Overall, we had about a 96 percent cure rate from our Phase 2 clinical trial.”
In order to go to Phase 3 trials, Stein says, “We’ll either have to do another round of fundraising or bring on a strategic partner.” He says he wants to begin those trials by early next year.
The company has advanced rapidly over the past two years, which Stein says is a testament to the company’s success recruiting key … Next Page »
By posting a comment, you agree to our terms and conditions.